Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Sponsor: Akeso
Summary
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Official title: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
469
Start Date
2024-08-02
Completion Date
2026-05-23
Last Updated
2025-03-12
Healthy Volunteers
No
Conditions
Interventions
AK104
intravenous
Lenvatinib
oral
TACE
TACE (chemo and embolic agent injection into the hepatic artery)
Placebo for AK104
intravenous
Placebo for Lenvatinib
oral
Locations (4)
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China